Patents by Inventor David Filpula
David Filpula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080063632Abstract: The invention provides a recombinant Escherichia coli host cell for producing an Escherichia coli-asparaginase II enzyme. The host cell includes an Escherichia coli chromosome and at least one copy of a recombinant extrachromosomal vector, wherein the recombinant extrachromosomal vector encodes the L-asparaginase II enzyme, wherein the host cell chromosome also encodes the same L-asparaginase II enzyme, and wherein the host chromosome does not encode any other isoform of L-asparaginase II.Type: ApplicationFiled: June 8, 2007Publication date: March 13, 2008Inventors: David Filpula, Maoliang Wang
-
Publication number: 20070259405Abstract: A new nucleic acid molecule that is codon-optimized to express beta interferon in Escherichia coli with greater efficacy.Type: ApplicationFiled: July 26, 2005Publication date: November 8, 2007Applicant: ENZON PHARMACEUTICALS, INC.Inventors: David Filpula, Amartya Basu
-
Publication number: 20060063715Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: ApplicationFiled: September 29, 2005Publication date: March 23, 2006Inventors: Marc Whitlow, James Wood, Karl Hardman, Robert Bird, David Filpula, Michele Rollence
-
Publication number: 20050048064Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: ApplicationFiled: August 2, 2004Publication date: March 3, 2005Inventors: Marc Whitlow, Robert Shorr, David Filpula, Lihsyng Lee
-
Publication number: 20050042680Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.Type: ApplicationFiled: April 23, 2004Publication date: February 24, 2005Inventors: David Filpula, Karen Yang, Amartya Basu, Maoliang Wang
-
Publication number: 20050008650Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: ApplicationFiled: August 10, 2004Publication date: January 13, 2005Inventors: Marc Whitlow, Robert Shorr, David Filpula, Lihsyng Lee
-
Patent number: 6743908Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: GrantFiled: September 20, 2001Date of Patent: June 1, 2004Assignee: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Patent number: 6743896Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: GrantFiled: September 20, 2001Date of Patent: June 1, 2004Assignee: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Patent number: 6515110Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: November 19, 1999Date of Patent: February 4, 2003Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
-
Publication number: 20020161201Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: ApplicationFiled: September 20, 2001Publication date: October 31, 2002Applicant: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Publication number: 20020155498Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: ApplicationFiled: September 20, 2001Publication date: October 24, 2002Applicant: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Patent number: 6323322Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: GrantFiled: April 30, 1998Date of Patent: November 27, 2001Assignee: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Patent number: 6121424Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: October 5, 1998Date of Patent: September 19, 2000Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
-
Patent number: 6103889Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: October 14, 1998Date of Patent: August 15, 2000Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, Karl D. Hardman, Robert E. Bird, David Filpula
-
Patent number: 6027725Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: October 5, 1998Date of Patent: February 22, 2000Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
-
Patent number: 6025165Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: October 5, 1998Date of Patent: February 15, 2000Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
-
Patent number: 5869620Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: February 22, 1995Date of Patent: February 9, 1999Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
-
Patent number: 5767260Abstract: Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.Type: GrantFiled: August 16, 1995Date of Patent: June 16, 1998Assignee: Enzon Inc.Inventors: Marc Whitlow, David Filpula, Robert Shorr
-
Patent number: 5763733Abstract: Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.Type: GrantFiled: October 13, 1994Date of Patent: June 9, 1998Assignee: Enzon, Inc.Inventors: Marc Whitlow, David Filpula, Robert Shorr
-
Patent number: 5202256Abstract: Vectors are provided that are capable of expressing, in microbial transformants, a protein having the native amino acid sequence of a bioadhesive precursor protein of a marine animal selected from the group consisting of mussels, barnacles, and oysters. The bioadhesive precursor protein can be expressed in transformants, recovered and converted to a bioadhesive protein by hydroxylation.Type: GrantFiled: August 16, 1991Date of Patent: April 13, 1993Assignee: Enzon Labs, Inc.Inventors: Kathy J. Maugh, David M. Anderson, Robert Strausberg, Susan L. Strausberg, Russ McCandliss, Tena Wei, David Filpula